Synthesis and in vitro study of modified chitosan-polycaprolactam nanocomplex as delivery system

In this work, chitosan/polycaprolactam (PCL-CS) nano-complex was synthesized and their micelles were formed as self-assembled amphiphilic nano-compartments. These micelles were utilize for drug delivery after loading quercetin (QU) as chemotherapeutic agent and delivery potency of this nano-complex...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of biological macromolecules 2018-07, Vol.113, p.1287-1293
Hauptverfasser: Rezvani, Melina, Mohammadnejad, Javad, Narmani, Asghar, Bidaki, Kazem
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this work, chitosan/polycaprolactam (PCL-CS) nano-complex was synthesized and their micelles were formed as self-assembled amphiphilic nano-compartments. These micelles were utilize for drug delivery after loading quercetin (QU) as chemotherapeutic agent and delivery potency of this nano-complex was investigated. This nano-complex was also functionalized with folic acid (FA) in order to targeting delivery of nano-carrier to cancer cell lines. This foure dimensional nano-complex was successfully characterized based on UV–vis, FT-IR, DLS, and TGA analytical devices to confirm the synthesis. Drug loading was estimated 21.5% in final nano-carrier. In vitro drug release study was applied to investigation of QU release in PBS that was exhibited high potency of nano-complex in controlled drug release. Cell viability of assay was implemented to determination of biocompatibility, bioavailability and therapeutic potency of nano-complexes on different cancer and normal cell lines. Micelles demonstrated safety levels for 24 and 48 h post-treatment incubation and FA receptor mediated uptake of chitosan/polycaprolactam/folic acid/quercetin (PCL-CS-FA-QU) was exhibited excellent efficiency on inhibition of cancer cells.
ISSN:0141-8130
1879-0003
DOI:10.1016/j.ijbiomac.2018.02.141